KOR

e-Article

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer Cells (NAM-NK) in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)
Document Type
Journal
Source
BLOOD; NOV 13 2019, 134 3p. Supplement: 1
Subject
Language
English
ISSN
15280020